6297-57-0

Upstream product

• 61-90-5 L-leucine 
• 1939-99-7 benzenesulfonyl chloride 
• 138535-51-0 N-(phenylmethanesulfonyl)-L-leucine methyl ester 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 1738-77-8 L-leucine benzyl ester p-toluenesulfonate 
• 102322-09-8 N-phenylmethanesulfonyl-L-leucine-(N'-phenyl-hydrazide) 

Downstream Products

• 131733-31-8 N-phenylmethanesulfonyl-L-leucyl chloride 
• 102322-09-8 N-phenylmethanesulfonyl-L-leucine-(N'-phenyl-hydrazide) 
• 663923-87-3 N-(phenylmethanesulfonyl)-L-leucyl-L-proline methyl ester 
• 663923-88-4 N-(phenylmethanesulfonyl)-L-leucyl-L-proline 
• 663923-89-5 1-[N²,N³-bis(tert-butyloxycarbonyl)guanidino]-4-(N-phenylmethanesulfonyl-L-leucyl-L-prolyl-amino)butane 
• 1374962-78-3 N-benzylsulfonyl-D,L-leucyl-L-proline-[(4-cyanophenyl)methyl]amide 
• 3253-28-9 N-(N-phenylmethanesulfonyl-L-leucyl)-L-leucine ethyl ester 
• 7474-68-2 N-(N-phenylmethanesulfonyl-L-leucyl)-L-leucine 
• 3303-31-9 L-leucyl-L-leucine 

Relevant academic research and scientific papers

MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF

Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases.

New cyanopeptide-derived low molecular weight inhibitors of trypsin-like serine proteases

This paper deals with the design, syntheses, and inhibition tests of new low molecular weight thrombin inhibitors utilizing cyanopeptides, the secondary metabolites of cyanobacteria with interesting biological activities, as new lead structures. Starting with aeruginosin 98-B (1) as a lead structure, we have developed and synthesised new, selective acting inhibitors of serine proteases (RA-1005 and RA-1009), which are suitable targets for further structure-activity studies.